Memantine in Patients With Chronic Glaucoma
Phase 3
Completed
- Conditions
- Open-Angle Glaucoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1179
- Registration Number
- NCT00168350
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 554
- Registration Number
- NCT00168337
A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia
Phase 2
Completed
- Conditions
- Postherpetic Neuralgia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 117
- Registration Number
- NCT00168441
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
Phase 3
Completed
- Conditions
- Hyperhidrosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 193
- Registration Number
- NCT00168402
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Biological: Botulinum Toxin Type AOther: placebo (saline)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 705
- Registration Number
- NCT00168428
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
Phase 4
Completed
- Conditions
- Hyperhidrosis
- Interventions
- Biological: Botulinum Toxin Type A
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 424
- Registration Number
- NCT00168480
A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis
Phase 4
Completed
- Conditions
- Hyperhidrosis
- Interventions
- Biological: Botulinum Toxin Type A
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 144
- Registration Number
- NCT00168415
Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- GlaucomaOcular Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 207
- Registration Number
- NCT00168363
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 494
- Registration Number
- NCT00168389
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Biological: Botulinum Toxin Type AOther: Placebo (saline)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 679
- Registration Number
- NCT00156910
© Copyright 2025. All Rights Reserved by MedPath